Kudriavzevii is an emerging fungal nosocomial pathogen [3] primarily found in the immunocompromised and those with hematological malignancies. Using the artemis antifungal surveillance program database, we describe geographic and temporal trends in the isolation of c Krusei from clinical specimens and the in vitro susceptibilities of 3,448 isolates to voriconazole as determined by clsi (formerly nccls) disk diffusion testing. Everything you need to know about candida krusei, an opportunistic fungal yeast pathogen that is emerging to be a significant health concern. Learn about candida krusei—symptoms, causes, drug resistance, and treatment options Expert insights on managing this rare candida species.
Candida krusei colonization was found in 41% of patients who received fluconazole prophylaxis compared with 17% of patients who received no prophylaxis The frequency of disseminated infection was 8% and 1%, respectively. To effectively address infections caused by candida krusei, it's crucial to thoroughly comprehend its nature and characteristics Understanding candida krusei not only helps in diagnosing infections accurately but also lays the groundwork for appropriate treatment strategies. Fluconazole is a commonly used azole antifungal drug that is effective against many candida species, but candida krusei tends to be inherently resistant to it This can limit the available treatment options and complicate the management of infections caused by this pathogen.
Candida krusei is a budding yeast of the saccharomycetaceae family The sac fungus is the predominant causal organism of candidosis (superficial infections of the skin) and candidemia (systemic affection of inner organs via the bloodstream).
WATCH
